Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Eyes Q3 SHASTA Data as REDEMPLO Approvals Build Momentum

Arrowhead Pharmaceuticals (NASDAQ:ARWR) executives said the company is entering a key period marked by new regulatory approvals, early commercial progress for REDEMPLO and upcoming Phase 3 data in severe hypertriglyceridemia, during a fireside chat at RBC Capital Markets’ 2026 Global Healthcare Conf

Arrowhead Pharmaceuticals Eyes $4B REDEMPLO Opportunity as RNAi Pipeline Readouts Near

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is moving into a more commercial phase while continuing to expand its RNA interference pipeline, Chief Executive Officer Chris Anzalone said during a presentation with BofA pharma and biotech analyst Jason Gerberry at the BofA Annual Healthcare Conference. An

Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform.

Goodbye, Mag 7! These 3 Buy-Rated Small-Cap Stocks Are Starting to Outperform.

As investors rotate away from the Magnificent 7, buy-rated small-caps like Chemours, Hillenbrand, and Arrowhead Pharmaceuticals are gaining momentum thanks to smart deals, analyst upgrades, and fresh operational catalysts.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Tuesday.

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

Where Arrowhead Pharmaceuticals Stands With Analysts

Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Arrowhead Pharmaceuticals: Q2 Earnings Insights

Arrowhead Pharmaceuticals: Q2 Earnings Insights

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Arrowhead Pharmaceuticals's Return On Capital Employed Insights

Arrowhead Pharmaceuticals's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of $62.87 million.

Recap: Arrowhead Pharmaceuticals Q1 Earnings

Recap: Arrowhead Pharmaceuticals Q1 Earnings

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Coinbase Global

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

377,756 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play